Outcomes of Pediatric Osteogenesis Imperfecta Patients Requiring Port‐a‐Cath Placement for Long‐Term Vascular Access

ABSTRACT Intravenous (iv) bisphosphonates are widely used to treat the skeletal manifestations of osteogenesis imperfecta (OI). Obtaining peripheral iv access in pediatric patients with OI is often difficult and traumatic. Although this may be mitigated with surgically placed iv ports (port‐a‐caths)...

Full description

Bibliographic Details
Main Authors: Andrew C White, Jay J Byrd, Makayla Schissel, Elizabeth Strudthoff, Maegen Wallace
Format: Article
Language:English
Published: Wiley 2023-07-01
Series:JBMR Plus
Subjects:
Online Access:https://doi.org/10.1002/jbm4.10752
_version_ 1797781822910758912
author Andrew C White
Jay J Byrd
Makayla Schissel
Elizabeth Strudthoff
Maegen Wallace
author_facet Andrew C White
Jay J Byrd
Makayla Schissel
Elizabeth Strudthoff
Maegen Wallace
author_sort Andrew C White
collection DOAJ
description ABSTRACT Intravenous (iv) bisphosphonates are widely used to treat the skeletal manifestations of osteogenesis imperfecta (OI). Obtaining peripheral iv access in pediatric patients with OI is often difficult and traumatic. Although this may be mitigated with surgically placed iv ports (port‐a‐caths), surgeons may be hesitant to perform this procedure on these children because of the lack of safety data. This study aims to gain better insight into the safety and efficacy of port‐a‐cath use in this population and identify risk factors for port‐a‐cath complications. In the present study, we conducted a retrospective cohort analysis of patient characteristics and the incidence of port‐a‐cath‐related complications in children with OI. Fifty‐three port‐a‐caths were placed in 29 children (21 males and 8 females). Of the 29 patients, most are OI type III (n = 18), followed by type I (n = 4), type IV (n = 4), and type V (n = 3). At the time of initial port‐a‐cath placement, the median age was 52 months (10–191 months), and the median weight was 7.9 kg (5.1–41.1 kg). Most patients (n = 20) weighed less than 10 kg during initial placement. Weight correlated significantly with OI type (p = 0.048), sex (p = 0.03), and vessel used (p = 0.02). Median initial port‐a‐cath longevity was 43 months (1–113 months), and we found no significant difference in port‐a‐cath longevity between sexes, OI types, or vessels used. Most patients (n = 19) required multiple port‐a‐cath placements. There is a significant difference (p = 0.02) between the number of placements and OI type, with type IV having more than type III. Port‐a‐cath removal was almost always due to mechanical complications (n = 19) but also for infection (n = 1) and malposition (n = 1). Eight patients still had their initial port‐a‐caths in place at the conclusion of this study. These findings indicate that complications associated with port‐a‐cath placement are mild and can be used to safely deliver iv bisphosphonates to pediatric OI patients. © 2023 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.
first_indexed 2024-03-13T00:02:24Z
format Article
id doaj.art-e5de33abd6db4753a92b37074c2d32af
institution Directory Open Access Journal
issn 2473-4039
language English
last_indexed 2024-03-13T00:02:24Z
publishDate 2023-07-01
publisher Wiley
record_format Article
series JBMR Plus
spelling doaj.art-e5de33abd6db4753a92b37074c2d32af2023-07-13T08:16:43ZengWileyJBMR Plus2473-40392023-07-0177n/an/a10.1002/jbm4.10752Outcomes of Pediatric Osteogenesis Imperfecta Patients Requiring Port‐a‐Cath Placement for Long‐Term Vascular AccessAndrew C White0Jay J Byrd1Makayla Schissel2Elizabeth Strudthoff3Maegen Wallace4College of Medicine University of Nebraska Medical Center Omaha NE USACollege of Medicine University of Nebraska Medical Center Omaha NE USADepartment of Biostatistics, College of Public Health University of Nebraska Medical Center Omaha NE USAThe Child Health Research Institute University of Nebraska Medical Center Omaha NE USAChildren's Hospital and Medical Center Omaha NE USAABSTRACT Intravenous (iv) bisphosphonates are widely used to treat the skeletal manifestations of osteogenesis imperfecta (OI). Obtaining peripheral iv access in pediatric patients with OI is often difficult and traumatic. Although this may be mitigated with surgically placed iv ports (port‐a‐caths), surgeons may be hesitant to perform this procedure on these children because of the lack of safety data. This study aims to gain better insight into the safety and efficacy of port‐a‐cath use in this population and identify risk factors for port‐a‐cath complications. In the present study, we conducted a retrospective cohort analysis of patient characteristics and the incidence of port‐a‐cath‐related complications in children with OI. Fifty‐three port‐a‐caths were placed in 29 children (21 males and 8 females). Of the 29 patients, most are OI type III (n = 18), followed by type I (n = 4), type IV (n = 4), and type V (n = 3). At the time of initial port‐a‐cath placement, the median age was 52 months (10–191 months), and the median weight was 7.9 kg (5.1–41.1 kg). Most patients (n = 20) weighed less than 10 kg during initial placement. Weight correlated significantly with OI type (p = 0.048), sex (p = 0.03), and vessel used (p = 0.02). Median initial port‐a‐cath longevity was 43 months (1–113 months), and we found no significant difference in port‐a‐cath longevity between sexes, OI types, or vessels used. Most patients (n = 19) required multiple port‐a‐cath placements. There is a significant difference (p = 0.02) between the number of placements and OI type, with type IV having more than type III. Port‐a‐cath removal was almost always due to mechanical complications (n = 19) but also for infection (n = 1) and malposition (n = 1). Eight patients still had their initial port‐a‐caths in place at the conclusion of this study. These findings indicate that complications associated with port‐a‐cath placement are mild and can be used to safely deliver iv bisphosphonates to pediatric OI patients. © 2023 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.https://doi.org/10.1002/jbm4.10752BISPHOSPHONATESINFUSIONSOSTEOGENESIS IMPERFECTAPORT‐A‐CATH
spellingShingle Andrew C White
Jay J Byrd
Makayla Schissel
Elizabeth Strudthoff
Maegen Wallace
Outcomes of Pediatric Osteogenesis Imperfecta Patients Requiring Port‐a‐Cath Placement for Long‐Term Vascular Access
JBMR Plus
BISPHOSPHONATES
INFUSIONS
OSTEOGENESIS IMPERFECTA
PORT‐A‐CATH
title Outcomes of Pediatric Osteogenesis Imperfecta Patients Requiring Port‐a‐Cath Placement for Long‐Term Vascular Access
title_full Outcomes of Pediatric Osteogenesis Imperfecta Patients Requiring Port‐a‐Cath Placement for Long‐Term Vascular Access
title_fullStr Outcomes of Pediatric Osteogenesis Imperfecta Patients Requiring Port‐a‐Cath Placement for Long‐Term Vascular Access
title_full_unstemmed Outcomes of Pediatric Osteogenesis Imperfecta Patients Requiring Port‐a‐Cath Placement for Long‐Term Vascular Access
title_short Outcomes of Pediatric Osteogenesis Imperfecta Patients Requiring Port‐a‐Cath Placement for Long‐Term Vascular Access
title_sort outcomes of pediatric osteogenesis imperfecta patients requiring port a cath placement for long term vascular access
topic BISPHOSPHONATES
INFUSIONS
OSTEOGENESIS IMPERFECTA
PORT‐A‐CATH
url https://doi.org/10.1002/jbm4.10752
work_keys_str_mv AT andrewcwhite outcomesofpediatricosteogenesisimperfectapatientsrequiringportacathplacementforlongtermvascularaccess
AT jayjbyrd outcomesofpediatricosteogenesisimperfectapatientsrequiringportacathplacementforlongtermvascularaccess
AT makaylaschissel outcomesofpediatricosteogenesisimperfectapatientsrequiringportacathplacementforlongtermvascularaccess
AT elizabethstrudthoff outcomesofpediatricosteogenesisimperfectapatientsrequiringportacathplacementforlongtermvascularaccess
AT maegenwallace outcomesofpediatricosteogenesisimperfectapatientsrequiringportacathplacementforlongtermvascularaccess